1. Scrip
  2. >>Business
  3. >>Earnings

Vertex Outlines Next Development Steps For Suzetrigine In Pain

 
• By Jessica Merrill

The company has accelerated a Phase II trial testing the NaV1.8 inhibitor in lumbosacral radiculopathy, and a Phase III trial in diabetic peripheral neuropathy will start this quarter.

Vertex updated investors on its diversification strategy • Source: Shutterstock

Vertex Pharmaceuticals Incorporated is already awaiting US Food and Drug Administration approval for its NaV1.8 inhibitor suzetrigine for the treatment of moderate-to-severe acute pain, but the company is advancing the drug into other late-stage clinical trials, with an eye toward expansion in peripheral neuropathic pain.

Key Takeaways
  • Vertex updated investors on Phase III development plans for the NaV1.8 inhibitor suzetrigine and povetacicept for IgA nephropathy (IgAN).

The company updated investors on the development of suzetrigine and other next-generation NaV1.8 and NaV1.7 inhibitors during its second quarter...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By Andy Smith

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.